[Federal Register Volume 59, Number 129 (Thursday, July 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-16366]


[[Page Unknown]]

[Federal Register: July 7, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces forthcoming meetings of public advisory 
committees of the Food and Drug Administration (FDA). This notice also 
summarizes the procedures for the meetings and methods by which 
interested persons may participate in open public hearings before FDA's 
advisory committees.

MEETING: The following advisory committee meetings are announced:
 Subcommittee Meeting of the National Task Force on AIDS Drug 
Development on Drug Development Issues
    Date, time, and place. July 19, 1994, 12:30 p.m., Sheraton National 
Hotel, 900 South Orme St., Arlington, VA.
    Type of meeting and contact person. Open subcommittee discussion, 
12:30 p.m. to 2 p.m.; open public hearing, 2 p.m. to 3 p.m., unless 
public participation does not last that long; Jean H. McKay, Office of 
AIDS and Special Health Issues (HF-12), Food and Drug Administration, 
5600 Fishers Lane, Rockville, MD 20857, 301-443-0104.
    General function of the task force. The National Task Force on AIDS 
Drug Development shall identify any barriers and provide creative 
options for the rapid development and evaluation of treatments for 
human immunodeficiency virus (HIV) infection and its sequelae. It also 
advises on issues related to such barriers, and provides options for 
the elimination of these barriers.
    Open task force discussion. The subcommittee will present, hear, 
and discuss issues on the barriers to the development of drugs for 
acquired immunodeficiency syndrome (AIDS) from the perspective of the 
subcommittee members, members of the Federal government, and the 
public.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the task force. Those desiring to make formal presentations should 
notify the contact person before July 13, 1994, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time required to make their comments.
 Subcommittee Meeting of the National Task Force on AIDS Drug 
Development on Public/Private Issues
    Date, time, and place. July 19, 1994, 1 p.m., Sheraton National 
Hotel, South Ballroom, 900 South Orme St., Arlington, VA.
     Type of meeting and contact person. Open subcommittee discussion, 
1 p.m. to 3 p.m.; open public hearing, 3 p.m. to 4 p.m., unless public 
participation does not last that long; Jean H. McKay, Office of AIDS 
and Special Health Issues (HF-12), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-443-0104.
    General function of the task force. The National Task Force on AIDS 
Drug Development shall identify any barriers and provide creative 
options for the rapid development and evaluation of treatments for HIV 
infection and its sequelae. It also advises on issues related to such 
barriers, and provides options for the elimination of these barriers.
    Open task force discussion. The subcommittee will present, hear, 
and discuss issues on the barriers to collaboration on AIDS drug 
development from the perspective of the subcommittee members, members 
of the Federal government, and the public.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the task force. Those desiring to make formal presentations should 
notify the contact person before July 13, 1994, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time required to make their comments.
    FDA public advisory committee meetings may have as many as four 
separable portions: (1) An open public hearing, (2) an open committee 
discussion, (3) a closed presentation of data, and (4) a closed 
committee deliberation. Every advisory committee meeting shall have an 
open public hearing portion. Whether or not it also includes any of the 
other three portions will depend upon the specific meeting involved. 
There are no closed portions for the meetings announced in this notice. 
The dates and times reserved for the open portions of each committee 
meeting are listed above.
    The open public hearing portion of each meeting shall be at least 1 
hour long unless public participation does not last that long. It is 
emphasized, however, that the 1 hour time limit for an open public 
hearing represents a minimum rather than a maximum time for public 
participation, and an open public hearing may last for whatever longer 
period the committee chairperson determines will facilitate the 
committee's work.
    Public hearings are subject to FDA's guideline (subpart C of 21 CFR 
part 10) concerning the policy and procedures for electronic media 
coverage of FDA's public administrative proceedings, including hearings 
before public advisory committees under 21 CFR part 14. Under 21 CFR 
10.205, representatives of the electronic media may be permitted, 
subject to certain limitations, to videotape, film, or otherwise record 
FDA's public administrative proceedings, including presentations by 
participants.
    Meetings of advisory committees shall be conducted, insofar as is 
practical, in accordance with the agenda published in this Federal 
Register notice. Changes in the agenda will be announced at the 
beginning of the open portion of a meeting.
    Any interested person who wishes to be assured of the right to make 
an oral presentation at the open public hearing portion of a meeting 
shall inform the contact person listed above, either orally or in 
writing, prior to the meeting. Any person attending the hearing who 
does not in advance of the meeting request an opportunity to speak will 
be allowed to make an oral presentation at the hearing's conclusion, if 
time permits, at the chairperson's discretion.
    The agenda, the questions to be addressed by the committee, and a 
current list of committee members will be available at the meeting 
location on the day of the meeting.
    Transcripts of the open portion of the meeting may be requested in 
writing from the Freedom of Information Office (HFI-35), Food and Drug 
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, 
approximately 15 working days after the meeting, at a cost of 10 cents 
per page. The transcript may be viewed at the Dockets Management Branch 
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., 
Rockville, MD 20857, approximately 15 working days after the meeting, 
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary 
minutes of the open portion of the meeting may be requested in writing 
from the Freedom of Information Office (address above) beginning 
approximately 90 days after the meeting.
    This notice is issued under section 10(a)(1) and (2) of the Federal 
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR 
part 14) on advisory committees.

    Dated: June 30, 1994.
 Linda A. Suydam,
 Interim Deputy Commissioner for Operations.
[FR Doc. 94-16366 Filed 7-6-94; 8:45 am]
BILLING CODE 4160-01-F